1 – 10 of 40
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
GPR30 in breast cancer - from molecular mechanisms to clinical outcome
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2021
-
Mark
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
(
- Contribution to journal › Article
-
Mark
CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial
(
- Contribution to journal › Article
- 2020
-
Mark
Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis
(
- Contribution to journal › Article
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article
- 2018
-
Mark
Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment
2018)(
- Thesis › Doctoral thesis (compilation)
- 2017
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
- 2016
-
Mark
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
(
- Contribution to journal › Article
-
Mark
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
(
- Contribution to journal › Article